



NDA 203952/S-011

SUPPLEMENT APPROVAL

AbbVie Inc.
Attention: Rubina Mondal MS
Associate Director, Regulatory Affairs
1 N. Waukegan Road
Dept. PA72/Bldg. AP30
North Chicago, IL 60064

Dear Dr. Mondal:

Please refer to your supplemental new drug application (sNDA) dated December 17, 2019, received December 17, 2019, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Duopa (Carbidopa and Levodopa) Enteral Suspension.

This “Changes Being Effected” supplemental new drug application provides for the addition of abscess, sepsis, and pneumonia in section 5.1 of the Warnings and Precautions section, and in the Patient Counseling Information section of the Duopa USPI. These changes are to align with revisions made in the Instructions for Use (IFU) for the AbbVie PEG and J tubes, based on earlier request from CDRH.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact Stacy Metz, PharmD, Senior Regulatory Project Manager, at stacy.metz@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Eric Bastings, MD
Director (acting)
Division of Neurology 1
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide
 - Instructions for Use

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ERIC P BASTINGS
05/21/2020 09:47:07 AM